IP Library Granted Patent US 7,605,241
Granted Patent B2
US 7,605,241 · App. 11/794,969 · Granted Oct 20, 2009

Synthesis of inhibitors of p90Rsk

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,605,241
App. No.
11/794,969
Granted
Oct 20, 2009
Kind
B2
Abstract

The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural product and has provided access to material sufficient for detailed biological evaluation.

Claims (23)

1. A method for synthesizing a compound having the general structure of formula I:

wherein R 1 and R 2 are each independently selected from the group consisting of OH and OAc, and R 3 is OAc;

said method comprising;

synthesizing from naringenin a flavonol (4)

wherein the conditions for step c 1 comprise TFA:H 2 O (20:2), CH 2 Cl 2 , (93%);

synthesizing a carbohydrate moiety by synthesizing from L-rhamnose compound 5

synthesizing rhamnosyl bromide from compound 5, and then condensing 4 and the rhamnosyl bromide.

2. The method of claim 1 , said method comprising synthetic schemes 1, 2, and 3;

wherein synthetic scheme 1 comprises the following steps;

wherein the conditions for step a 1 comprise BnBr, K 2 CO 3 , acetone, reflux, (81%),

wherein the conditions for step b 1 comprise cat. I 2 , DMSO, 140° C., (72%),

wherein the conditions for step c 1 comprise DMDO, acetone, CH 2 Cl 2 , 0° C., then pTsOH, CHCl 3 , (78%);

wherein synthetic scheme 2 comprises the following steps;

wherein the conditions for step a comprise 2,3 butanedione, CH(OMe) 3 , cat. CSA, MeOH, reflux, (89%);

wherein the conditions for step b comprise BnBr, NaH, THF, reflux, (85%);

wherein the conditions for step c comprise TFA:H 2 O (20:2), CH 2 Cl 2 , (93%);

wherein the condition for step d comprise Ac 2 O, NEt 3 , cat. DMAP, CH 2 Cl 2 , (100%);

wherein the conditions for step e comprise Br 2 , CH 2 Cl 2 , 0° C., (84%); and

wherein synthetic scheme 3 comprises the following steps;

3. The method of claim 1 , further wherein said compound has 90 kDa ribosomal S6 kinase inhibitory activity.

4. The method of claim 3 , wherein R 1 is OH and R 2 is OAc.

5. The method of claim 3 , wherein R 1 is OH and R 2 is OH.

6. The method of claim 3 , wherein R 1 is OAc and R 2 is OH.

Assignments (2)
SECURITY INTEREST Recorded Mar 9, 2022
From: LUNA LABS USA, LLC
To: M&T BANK
Reel/Frame 059211/0861 →
CONFIRMATORY LICENSE Recorded Jun 3, 2008
From: UNIVERSITY OF VIRGINIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021032/0231 →